Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1982 1
1983 1
1986 1
1987 1
1988 1
1990 4
1991 2
1994 4
1995 6
1996 3
1997 9
1998 7
1999 8
2000 3
2001 5
2002 9
2003 8
2004 8
2005 10
2006 7
2007 9
2008 3
2009 7
2010 4
2011 4
2012 1
2013 1
2014 5
2015 5
2016 10
2017 8
2018 8
2019 8
2020 6
2021 14
2022 8
2023 6
2024 10
2025 8
2026 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

202 results

Results by year

Filters applied: Meta-Analysis, Randomized Controlled Trial. Clear all
Page 1
Dydrogesterone in the treatment of endometriosis: evidence mapping and meta-analysis.
Peng C, Huang Y, Zhou Y. Peng C, et al. Arch Gynecol Obstet. 2021 Jul;304(1):231-252. doi: 10.1007/s00404-020-05900-z. Epub 2021 Jan 4. Arch Gynecol Obstet. 2021. PMID: 33398505 Free PMC article.
Compared with GnRH-a, dydrogesterone also lowered the risk of endometriosis recurrence and elevated transaminase levels. ...CONCLUSIONS: The amount and quality of evidence evaluating the effects of dydrogesterone for the treatment of endometriosis is generally very …
Compared with GnRH-a, dydrogesterone also lowered the risk of endometriosis recurrence and elevated transaminase levels. ...CONCLUSIO …
Oral dydrogesterone versus micronized vaginal progesterone for luteal phase support: a double-blind crossover study investigating pharmacokinetics and impact on the endometrium.
Loreti S, Thiele K, De Brucker M, Olsen C, Centelles-Lodeiro J, Bourgain C, Waelput W, Tournaye H, Griesinger G, Raes J, Vieira-Silva S, Arck P, Blockeel C, Mackens S. Loreti S, et al. Hum Reprod. 2024 Feb 1;39(2):403-412. doi: 10.1093/humrep/dead256. Hum Reprod. 2024. PMID: 38110714
STUDY QUESTION: How do plasma progesterone (P) and dydrogesterone (D) concentrations together with endometrial histology, transcriptomic signatures, and immune cell composition differ when oral dydrogesterone (O-DYD) or micronized vaginal progesterone (MVP) is used …
STUDY QUESTION: How do plasma progesterone (P) and dydrogesterone (D) concentrations together with endometrial histology, transcripto …
Dydrogesterone as an oral alternative to vaginal progesterone for IVF luteal phase support: A systematic review and individual participant data meta-analysis.
Griesinger G, Blockeel C, Kahler E, Pexman-Fieth C, Olofsson JI, Driessen S, Tournaye H. Griesinger G, et al. PLoS One. 2020 Nov 4;15(11):e0241044. doi: 10.1371/journal.pone.0241044. eCollection 2020. PLoS One. 2020. PMID: 33147288 Free PMC article.
The aim of this systematic review and meta-analysis was to conduct a comprehensive assessment of the evidence on the efficacy and safety of oral dydrogesterone versus micronized vaginal progesterone (MVP) for luteal phase support. Embase and MEDLINE were searched for studi …
The aim of this systematic review and meta-analysis was to conduct a comprehensive assessment of the evidence on the efficacy and safety of …
Oral dydrogesterone vs. vaginal progesterone capsules for luteal-phase support in women undergoing embryo transfer: a systematic review and meta-analysis.
Barbosa MWP, Valadares NPB, Barbosa ACP, Amaral AS, Iglesias JR, Nastri CO, Martins WP, Nakagawa HM. Barbosa MWP, et al. JBRA Assist Reprod. 2018 Jun 1;22(2):148-156. doi: 10.5935/1518-0557.20180018. JBRA Assist Reprod. 2018. PMID: 29488367 Free PMC article.
CONCLUSIONS: Good quality evidence from RCTs suggest that oral dydrogesterone provides at least similar reproductive outcomes than vaginal progesterone capsules when used for LPS in women undergoing embryo transfers. Dydrogesterone is a reasonable option and the cho …
CONCLUSIONS: Good quality evidence from RCTs suggest that oral dydrogesterone provides at least similar reproductive outcomes than va …
Efficacy of dydrogesterone on treating recurrent miscarriage and its influence on immune factors: a systematic review and meta-analysis.
Guo H, Lu Q. Guo H, et al. Ann Palliat Med. 2021 Oct;10(10):10971-10985. doi: 10.21037/apm-21-2605. Ann Palliat Med. 2021. PMID: 34763460 Free article.
BACKGROUND: This study aimed to explore the clinical efficacy of dydrogesterone in treating recurrent spontaneous abortion (RSA), analyze the influence of dydrogesterone on cellular immune factors, and provide evidence for clinical medication. ...The experimental gr …
BACKGROUND: This study aimed to explore the clinical efficacy of dydrogesterone in treating recurrent spontaneous abortion (RSA), ana …
Dydrogesterone vs progesterone for luteal-phase support: systematic review and meta-analysis of randomized controlled trials.
Barbosa MW, Silva LR, Navarro PA, Ferriani RA, Nastri CO, Martins WP. Barbosa MW, et al. Ultrasound Obstet Gynecol. 2016 Aug;48(2):161-70. doi: 10.1002/uog.15814. Epub 2016 Jul 8. Ultrasound Obstet Gynecol. 2016. PMID: 26577241 Free article.
OBJECTIVES: To compare the effects of dydrogesterone and progesterone for luteal-phase support (LPS) in women undergoing assisted reproductive techniques (ART). ...Two of the three studies reporting on dissatisfaction of treatment identified lower levels of dissatisfaction …
OBJECTIVES: To compare the effects of dydrogesterone and progesterone for luteal-phase support (LPS) in women undergoing assisted rep …
Oral dydrogesterone along with vaginal micronized progesterone supplementation for luteal phase support in IVF patients, and its impact on pregnancy and live birth rates: a prospective randomized trial.
Rinaldi L, Crescenzi F, Selman H. Rinaldi L, et al. BMC Pregnancy Childbirth. 2024 Dec 21;24(1):845. doi: 10.1186/s12884-024-07069-8. BMC Pregnancy Childbirth. 2024. PMID: 39709390 Free PMC article. Clinical Trial.
The patients were randomized into two groups based on the type of luteal phase support route: Group A, control group (n = 310) patients received our routine LPS protocol which consists of the administration of 800 mg of micronized vaginal progesterone and Group B, study group, (n …
The patients were randomized into two groups based on the type of luteal phase support route: Group A, control group (n = 310) patients rece …
Oral dydrogesterone in frozen-thawed embryo transfer cycles.
Macedo LCGM, Cavagna Neto M, Dzik A, Rocha ADR, Lima SMRR. Macedo LCGM, et al. Rev Assoc Med Bras (1992). 2022 Jan;68(1):100-105. doi: 10.1590/1806-9282.20210874. Rev Assoc Med Bras (1992). 2022. PMID: 34909972 Free article. Clinical Trial.
A total of 73 patients were randomly selected and orally administered 40 mg/day dydrogesterone (dydrogesterone group, n=36) or 800 mg/day micronized vaginal progesterone (micronized vaginal progesterone group, n=37), after endometrial preparation with transdermal es …
A total of 73 patients were randomly selected and orally administered 40 mg/day dydrogesterone (dydrogesterone group, n=36) or …
A systematic review of dydrogesterone for the treatment of recurrent miscarriage.
Carp H. Carp H. Gynecol Endocrinol. 2015 Jun;31(6):422-30. doi: 10.3109/09513590.2015.1006618. Epub 2015 Mar 13. Gynecol Endocrinol. 2015. PMID: 25765519
The objective of this systematic review was to assesses whether the orally acting progestagen, dydrogesterone lowers the incidence of subsequent miscarriage in women with recurrent miscarriage. A computerized search was performed in Medline, Embase and Ovid Medline for ori …
The objective of this systematic review was to assesses whether the orally acting progestagen, dydrogesterone lowers the incidence of …
Ultra-low dose estradiol and dydrogesterone for the treatment of menopausal symptoms in a pooled, multi-ethnic population.
Stevenson JC, Ren M, Kahler E, Custodio MG, Nappi RE, Tatarchuk T, Simoncini T, Karpova V, Yu Q. Stevenson JC, et al. Maturitas. 2024 Dec;190:108117. doi: 10.1016/j.maturitas.2024.108117. Epub 2024 Sep 17. Maturitas. 2024. PMID: 39317030 Free article. Clinical Trial.
We evaluated the efficacy of an ultra-low dose combination of 0.5 mg estradiol and 0.25 mg dydrogesterone (E 0.5 mg/D 2.5 mg) in alleviating vasomotor symptoms across a multi-ethnic population. ...
We evaluated the efficacy of an ultra-low dose combination of 0.5 mg estradiol and 0.25 mg dydrogesterone (E 0.5 mg/D 2.5 mg) in alle …
202 results